456 related articles for article (PubMed ID: 21606170)
21. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
22. A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria.
Margolskee E; Mikita G; Rea B; Bagg A; Zuo Z; Sun Y; Goswami M; Wang SA; Oak J; Arber DA; Allen MB; George TI; Rogers HJ; Hsi E; Hasserjian RP; Orazi A
Mod Pathol; 2018 Jun; 31(6):873-880. PubMed ID: 29403082
[TBL] [Abstract][Full Text] [Related]
23. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
24. An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification.
Qiu S; Jiang E; Wei H; Lin D; Zhang G; Wei S; Zhou C; Liu K; Wang Y; Liu B; Liu Y; Gong B; Gong X; Feng S; Mi Y; Han M; Wang J
BMC Cancer; 2017 Aug; 17(1):534. PubMed ID: 28793875
[TBL] [Abstract][Full Text] [Related]
25. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
26. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
27. Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group.
Chisholm KM; Heerema-McKenney AE; Choi JK; Smith J; Ries RE; Hirsch BA; Raimondi SC; Alonzo TA; Wang YC; Aplenc R; Sung L; Gamis AS; Meshinchi S; Kahwash SB
Blood Adv; 2020 Dec; 4(23):6000-6008. PubMed ID: 33284945
[TBL] [Abstract][Full Text] [Related]
28. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
Senent L; Arenillas L; Luño E; Ruiz JC; Sanz G; Florensa L
Haematologica; 2013 Apr; 98(4):568-75. PubMed ID: 23065505
[TBL] [Abstract][Full Text] [Related]
29. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
30. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
31. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
[TBL] [Abstract][Full Text] [Related]
32. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.
Westers TM; Cremers EM; Oelschlaegel U; Johansson U; Bettelheim P; Matarraz S; Orfao A; Moshaver B; Brodersen LE; Loken MR; Wells DA; Subirá D; Cullen M; Te Marvelde JG; van der Velden VH; Preijers FW; Chu SC; Feuillard J; Guérin E; Psarra K; Porwit A; Saft L; Ireland R; Milne T; Béné MC; Witte BI; Della Porta MG; Kern W; van de Loosdrecht AA;
Haematologica; 2017 Feb; 102(2):308-319. PubMed ID: 27758818
[TBL] [Abstract][Full Text] [Related]
33. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.
Sandahl JD; Coenen EA; Forestier E; Harbott J; Johansson B; Kerndrup G; Adachi S; Auvrignon A; Beverloo HB; Cayuela JM; Chilton L; Fornerod M; de Haas V; Harrison CJ; Inaba H; Kaspers GJ; Liang DC; Locatelli F; Masetti R; Perot C; Raimondi SC; Reinhardt K; Tomizawa D; von Neuhoff N; Zecca M; Zwaan CM; van den Heuvel-Eibrink MM; Hasle H
Haematologica; 2014 May; 99(5):865-72. PubMed ID: 24441146
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
Guillem V; Calabuig M; Brunet S; Esteve J; Escoda L; Gallardo D; Ribera JM; Queipo de Llano MP; Arnan M; Pedro C; Amigo ML; Martí-Tutusaus JM; García-Guiñón A; Bargay J; Sampol A; Salamero O; Font L; Talarn C; Hoyos M; Díaz-Beyá M; Garrido A; Navarro B; Nomdédeu J; Sierra J; Tormo M
Leuk Lymphoma; 2018 Oct; 59(10):2383-2393. PubMed ID: 29345176
[TBL] [Abstract][Full Text] [Related]
35. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
36. [Clinical and Cytogenetical Characteristics in Acute Myeloid Leukemia with Myelodysplasia-Related Changes].
Ma JL; Zhou AQ; Gu SY; Chen BA; Ge Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1757-1762. PubMed ID: 34893106
[TBL] [Abstract][Full Text] [Related]
37. Acute Myeloid Leukemia with Myelodysplasia - Related Changes after Isolated Myeloid Sarcoma.
Li X; Yin J; Li L
Clin Lab; 2024 May; 70(5):. PubMed ID: 38747915
[TBL] [Abstract][Full Text] [Related]
38. Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology.
Cho YU; Jang S; Seo EJ; Park CJ; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park SH; Park YM; Lee JK
Leuk Lymphoma; 2015; 56(8):2301-8. PubMed ID: 25487075
[TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
[TBL] [Abstract][Full Text] [Related]
40. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
